posted on 2020-02-24, 12:34authored byNa Le Dang, Matthew K. Matlock, Tyler B. Hughes, S. Joshua Swamidass
Metabolism of drugs
affects their absorption, distribution, efficacy,
excretion, and toxicity profiles. Metabolism is routinely assessed
experimentally using recombinant enzymes, human liver microsome, and
animal models. Unfortunately, these experiments are expensive, time-consuming,
and often extrapolate poorly to humans because they fail to capture
the full breadth of metabolic reactions observed in vivo. As a result, metabolic pathways leading to the formation of toxic
metabolites are often missed during drug development, giving rise
to costly failures. To address some of these limitations, computational
metabolism models can rapidly and cost-effectively predict sites of
metabolismthe atoms or bonds which undergo enzymatic modificationson
thousands of drug candidates, thereby improving the likelihood of
discovering metabolic transformations forming toxic metabolites. However,
current computational metabolism models are often unable to predict
the specific metabolites formed by metabolism at certain sites. Identification
of reaction type is a key step toward metabolite prediction. Phase
I enzymes, which are responsible for the metabolism of more than 90%
of FDA approved drugs, catalyze highly diverse types of reactions
and produce metabolites with substantial structural variability. Without
knowledge of potential metabolite structures, medicinal chemists cannot
differentiate harmful metabolic transformations from beneficial ones.
To address this shortcoming, we propose a system for simultaneously
labeling sites of metabolism and reaction types, by classifying them
into five key reaction classes: stable and unstable oxidations, dehydrogenation,
hydrolysis, and reduction. These classes unambiguously identify 21
types of phase I reactions, which cover 92.3% of known reactions in
our database. We used this labeling system to train a neural network
model of phase I metabolism on a literature-derived data set encompassing
20 736 human phase I metabolic reactions. Our model, Rainbow
XenoSite, was able to identify reaction-type specific sites of metabolism
with a cross-validated accuracy of 97.1% area under the receiver operator
curve. Rainbow XenoSite with five-color and combined output is available
for use free and online through our secure server at http://swami.wustl.edu/xenosite/p/phase1_rainbow.